Seeking Alpha

The FDA rejects Amgen's (AMGN) application to expand the use of the drug Xgeva to delay the...

The FDA rejects Amgen's (AMGN) application to expand the use of the drug Xgeva to delay the spread of tumors to the bone in patients suffering from advanced prostate cancer. It's a blow for Amgen, as analysts see Xgeva and a related osteoporosis drug Prolia as among the most important growth drivers for the company.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector